Unlocking New Horizons in Oncolytic Virus Research: a client collaboration story
Oncolytic viral immunotherapy harnesses the power of viruses to enter cells and take over their genetic machinery. There is growing interest in using virus-based therapies in cancer treatment because of their potential to target and kill tumour cells very specifically.
The viruses can be engineered to make them less likely to infect healthy cells, and boost the immune system’s own response against the tumours.
Since the first oncolytic viral immunotherapy was approved to treat melanoma back in 2015, there has been a lot of interest in virus-based therapies to treat cancer. While no more products have yet gained approval, numerous companies are working in the field, with multiple potentially life-changing products and strategies now in the clinic and preclinical development.
Oncodesign Services provides preclinical services to progress oncolytic virus into the clinic
Oncodesign Services has been working with ViraTherapeutics, an Austrian company and subsidiary of Boehringer Ingelheim, on their oncolytic viral immunotherapy since 2018. Our collaboration includes preclinical pharmacology evaluation and proof-of-concept work, and we continue to work with them as they develop their promising vesicular stomatitis virus variants as cancer treatments.
Fabrice Viviani, President & CEO of Oncodesign Services, said:
“We’re thrilled to continue our long-term relationships with ViraTherapeutics and able to impact cancer research with innovative ideas and technologies. Our teams are collaborating in a daily manner to support the (ViraTherapeutics Oncolytic Viruses) programs and select the best candidates with high level of trust and confidence. Oncolytic viruses open the door to new horizon for cancer patients. I’m confident that the team has all the resources and know-how in place to sustain the preclinical discovery investigations for this novel type of therapeutic modality.”
The potential of oncolytic viral immunotherapy to improve the prospects of cancer patients is enormous. Contact us if you want to know more about how Oncodesign Services can help you progress your oncolytic viruses into the clinic !
